Literature DB >> 36181568

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.

Yong Chen1, Jingqin Zhong2, Wei Sun2, Wangjun Yan2, Chunmeng Wang2, Wanlin Liu2, Xinyi Lin2, Zijian Zou2.   

Abstract

OPINION STATEMENT: Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a critical diagnostic biomarker in clinical practice. The introduction of targeted agents for BRAF-mutant melanoma has significantly improved overall survival in a large proportion of patients. However, there is BRAF inhibitor resistance in most patients, and its mechanisms are complicated and need further clarification. Additionally, treatment approaches to overcome resistance have evolved rapidly, shifting from monotherapy to multimodality treatment, which has dramatically improved patient outcomes in clinical trials and practice. This review highlights the mechanisms of BRAF inhibitor resistance in melanoma and discusses the current state of its therapeutic approaches that can be further explored in clinical practice.
© 2022. The Author(s).

Entities:  

Keywords:  BRAF inhibitor; BRAF mutation; Combination therapy; Melanoma; Resistance mechanism; Targeted therapy

Year:  2022        PMID： 36181568     DOI： 10.1007/s11864-022-01006-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  82 in total

1.  BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Authors:  Michael J Vido; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

2.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

3.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Authors:  Hubing Shi; Xiangju Kong; Antoni Ribas; Roger S Lo
Journal:  Cancer Res       Date:  2011-08-01       Impact factor: 12.701

4.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Authors:  Y N Vashisht Gopal; Wanleng Deng; Scott E Woodman; Kakajan Komurov; Prahlad Ram; Paul D Smith; Michael A Davies
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

Review 5.  BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.

Authors:  Jaquelyn N Sanchez; Ton Wang; Mark S Cohen
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Authors:  Douglas B Johnson; Alexander M Menzies; Lisa Zimmer; Zeynep Eroglu; Fei Ye; Shilin Zhao; Helen Rizos; Antje Sucker; Richard A Scolyer; Ralf Gutzmer; Helen Gogas; Richard F Kefford; John F Thompson; Jürgen C Becker; Carola Berking; Friederike Egberts; Carmen Loquai; Simone M Goldinger; Gulietta M Pupo; Willy Hugo; Xiangju Kong; Levi A Garraway; Jeffrey A Sosman; Antoni Ribas; Roger S Lo; Georgina V Long; Dirk Schadendorf
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

7.  Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Authors:  Paolo A Ascierto; Reinhard Dummer; Helen J Gogas; Keith T Flaherty; Ana Arance; Mario Mandala; Gabriella Liszkay; Claus Garbe; Dirk Schadendorf; Ivana Krajsova; Ralf Gutzmer; Jan Willem B de Groot; Carmen Loquai; Ashwin Gollerkeri; Michael D Pickard; Caroline Robert
Journal:  Eur J Cancer       Date:  2020-01-02       Impact factor: 9.162

8.  Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.

Authors:  Alan E Siroy; Genevieve M Boland; Denái R Milton; Jason Roszik; Silva Frankian; Jared Malke; Lauren Haydu; Victor G Prieto; Michael Tetzlaff; Doina Ivan; Wei-Lien Wang; Carlos Torres-Cabala; Jonathan Curry; Sinchita Roy-Chowdhuri; Russell Broaddus; Asif Rashid; John Stewart; Jeffrey E Gershenwald; Rodabe N Amaria; Sapna P Patel; Nicholas E Papadopoulos; Agop Bedikian; Wen-Jen Hwu; Patrick Hwu; Adi Diab; Scott E Woodman; Kenneth D Aldape; Rajyalakshmi Luthra; Keyur P Patel; Kenna R Shaw; Gordon B Mills; John Mendelsohn; Funda Meric-Bernstam; Kevin B Kim; Mark J Routbort; Alexander J Lazar; Michael A Davies
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551

9.  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Authors:  G V Long; K T Flaherty; D Stroyakovskiy; H Gogas; E Levchenko; F de Braud; J Larkin; C Garbe; T Jouary; A Hauschild; V Chiarion-Sileni; C Lebbe; M Mandalà; M Millward; A Arance; I Bondarenko; J B A G Haanen; J Hansson; J Utikal; V Ferraresi; P Mohr; V Probachai; D Schadendorf; P Nathan; C Robert; A Ribas; M A Davies; S R Lane; J J Legos; B Mookerjee; J-J Grob
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 10.  ERK/MAPK signalling pathway and tumorigenesis.

Authors:  Yan-Jun Guo; Wei-Wei Pan; Sheng-Bing Liu; Zhong-Fei Shen; Ying Xu; Ling-Ling Hu
Journal:  Exp Ther Med       Date:  2020-01-15       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.